Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer

被引：22

作者：

Karasawa K. ^{[1
,2
]}

Katsui K. ^{[3
]}

Seki K. ^{[1
]}

Kohno M. ^{[1
]}

Hanyu N. ^{[1
]}

Nasu S. ^{[1
]}

Muramatsu H. ^{[1
]}

Maebayashi K. ^{[1
]}

Mitsuhashi N. ^{[1
]}

Haga S. ^{[4
]}

Kimura T. ^{[5
]}

Takahashi I. ^{[6
]}

机构：

[1] Department of Radiology, Tokyo Women's Medical University School of Medicine

[2] Department of Radiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421

[3] Department of Radiology, Okayama University Graduate School of Medicine and Dentistry

[4] Department of Surgery, Tokyo Women's Medical University Daini Hospital

[5] Department of Surgery II, Tokyo Women's Medical University School of Medicine

[6] Department of Surgery, Edogawa Hospital

来源：

Breast Cancer | 2003年 / 10卷 / 3期

关键词：

Breast cancer; Concurrent chemotherapy; Docetaxel; Radiotherapy;

D O I：

10.1007/BF02966728

中图分类号：

学科分类号：

摘要：

Background: Docetaxel has shown remarkable radiosensitizing properties in vitro. In this study we investigated whether the addition of docetaxel to radiotherapy enhanced tumor response in patients with advanced or recurrent breast cancer. Methods: A total of 35 patients were enrolled in this study. Docetaxel was administered concurrently during radiotherapy. Radiation doses were 54 to 69 Gy (median 60 Gy). In those enrolled through January 2000, docetaxel 40 mg/m 2 was administered biweekly (once every two weeks), with subsequent dose adjustments based on tolerance and bone marrow and liver function. Beginning in February 2000, a weekly docetaxel schedule was used instead. This new regimen was based on data suggesting reduced myelosuppression with this regimen. The weekly dose rate was 20 mg/m 2, with dose reductions for impaired organ function. Results: All patients were evaluated for toxicity and response and a total of 40 irradiated sites were evaluated for local response. The overall response rate of irradiated sites was 95% and the CR rate was 68%. CR and PR were achieved in 40%, 37% of patients, respectively. Acute toxicities were tolerated by most patients: 17% had Grade 3-4 neutropenia, 6% had Grade 3-4 radiation dermatitis, and 3% had Grade 3-4 pneumonitis. Conclusion: The combination of docetaxel with radiotherapy is an active and safe regimen in patients with inoperable advanced or recurrent breast cancer. We determined the recommended dose of docetaxel with concomitant radiotherpy to be 20 mg/m 2 weekly for a Phase II study. Further study is necessary to assess the impact of this treatment on long-term outcome.

引用

页码：268 / 274

页数：6

共 22 条

[1]

Hennequin C., Giocanti N., Favaudon V., Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells, Cancer Res, 56, pp. 1842-1850, (1996)

[2]

Matsuura M., Hasegawa M., Hayakawa K., Kawashima M., Nasu S., Nakamura Y., Hayakawa K., Mitsuhashi N., Niibe H., Experimental study of the effects on apoptosis of docetaxel alone and in combination with irradiation, Oncol Rep, 7, pp. 289-293, (2000)

[3]

Mason K.A., Hunter N.R., Milas M., Abbruzzese J.L., Milas L., Docetaxel enhances tumor radioresponse in vivo, Clinical Cancer Research, 3, I12, pp. 2431-2438, (1997)

[4]

Mason K.A., Kishi K., Hunter N., Buchmiller L., Akimoto T., Komaki R., Milas L., Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo, Clinical Cancer Research, 5, 12, pp. 4191-4198, (1999)

[5]

Valero V., Holmes F.A., Walters R.S., Theriault R.L., Esparza L., Fraschini G., Fonseca G.A., Bellet R.E., Buzdar A.U., Hortobagyi G.N., Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer, J Clin Oncol, 13, pp. 2886-2894, (1995)

[6]

Taguchi T., Furue H., Niitani H., Ishitani K., Kanamaru R., Hasegawa K., Ariyoshi Y., Noda K., Furuse K., Fukuoka M., Yakushiji M., Kashimura M., Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug, Japanese Journal of Cancer and Chemotherapy, 21, 12, pp. 1997-2005, (1994)

[7]

Teng M., Choy H., De Vore R.D., Et al., Phase i trial of outpatient weekly docetaxel and concurrent therapy for stage IlI unresectable non-small-cell lung cancer: A vanderbilt cancer center affiliate network (VVCAN) trial (abstract), Proc Am Soc Clin Oncol, 17, (1998)

[8]

Hainsworth J.D., Burris III H.A., Erland J.B., Thomas M., Greco F.A., Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer, Journal of Clinical Oncology, 16, 6, pp. 2164-2168, (1998)

[9]

Koukourakis M.I., Bahlitzanakis N., Froudarakis M., Giatromanolaki A., Georgoulias V., Koumiotaki S., Christodoulou M., Kyrias G., Skarlatos J., Kostantelos J., Beroukas K., Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma, British Journal of Cancer, 80, 11, pp. 1792-1796, (1999)

[10]

Loftier T.M., Freund W., Droge C., Et al., Activity of weekly taxotere in patients with matastatic breast cancer, Proc Am Soc Clin Oncol, 16, (1998)

← 1 2 3 →